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OBJECTIVES: Analyze the nature of the relationship between
epoetin dose, hematocrit and mortality and determine if there
are any implications for establishing hematocrit targets.
METHODS: Hematocrit, epoetin dose, and other factors were
summarized during a 6-month period for incident ESRD patients
in the United States Renal Data System data. Mortality rates are
summarized over a 1-year follow-up. A Cox regression model
was used to evaluate the association between hematocrit, epoetin
dose, and mortality controlling for interaction between hemat-
ocrit and epoetin dose. RESULTS: Overall unadjusted mortality
rate was 251 per thousand patients. Analysis showed hematocrit
was inversely associated with epoetin dose. For the same
observed hematocrit levels, there were widely varying treatment-
related survival outcomes. In general, higher hematocrit level is
associated with lower mortality while higher epoetin dose is
associated with higher mortality. Compared to patients with an
observed study hematocrit of 33 to 36 percent and epoetin dose
in the ﬁrst dose quartile, the highest relative risk of death was
observed among patients with hematocrit values < 30 percent
and epoetin dose in the fourth dose quartile (RR = 2.14 and 95%
Ci = 1.88 to 2.42). CONCLUSIONS: Failure to control for
epoetin dosage will lead to misinterpretation of the correlation
between observed hematocrit and survival. Studies that reported
an association between hematocrit levels and survival did not
adequately control for epoetin dosage and the validity of the
inferred survival beneﬁt from increasing hematocrits is ques-
tionable. Previously published claims of a survival beneﬁt related
to higher hematocrit level should not be used to justify hemat-
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OBJECTIVES: In the treatment of benign prostatic hyperplasia
(BPH), patient and physician concerns regarding vasodilatory
side effects have led to the increased use of uroselective alpha-
blockade as ﬁrst-line therapy over less expensive, generic, non-
uroselective agents. This study evaluated the relative economic
impact of two currently available uroselective agents, alfuzosin
and tamsulosin. METHODS: A 1-year decision analysis was
undertaken to project the medical costs associated with treating
symptomatic BPH patients with alfuzosin vs. tamsulosin. Key
inputs included clinical data (efﬁcacy and adverse events [AEs]),
dosing, and routine medical care costs. Clinical data were
derived from a comprehensive meta-analysis published as part of
recently published BPH treatment guidelines, and resource uti-
lization information was obtained from published sources and
two nationwide physician surveys. RESULTS: Both agents had
similar efﬁcacy, however, safety proﬁles differed. Daily average
acquisition costs, after adjusting for average wholesale price for
tamsulosin ($1.99) and alfuzosin ($1.86) and increased daily
average consumption (DACON) (17% of patients required a
double dose of tamsulosin), were $1.98 vs. $1.58 per patient per
day for tamsulosin and alfuzosin, respectively. This difference
based upon price and DACON amounted to $146.00 per patient
per year (PPPY) (tamsulosin = $722.70, alfuzosin = $576.70).
Costs associated with tamsulosin-related AEs were estimated to
be $4.59 PPPY, whereas, alfuzosin-related AEs were $2.25 PPPY
($2.34 PPPY difference). Therefore, in considering the price and
DACON differential ($146.00) together with the differential in
costs of treating AEs ($2.34), alfuzosin saved $148.34 PPPY, 
a 20% difference. CONCLUSIONS: Alfuzosin provides cost
savings over tamsulosin in the treatment of patients with symp-
tomatic BPH. Savings are realized primarily on the basis of total
drug acquisition costs, followed by lower costs associated with
treating side effects of therapy. Alfuzosin is a less expensive alter-
native to tamsulosin as a ﬁrst-line clinically uroselective drug
therapy in the management of men with BPH.
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OBJECTIVES: This analysis addresses the cost-effectiveness of
the extended release formulation of oxybutynin (Ditropan XL)
relative to long-acting tolterodine (Detrol LA) for the treatment
of overactive bladder in the US. METHODS: A previously vali-
dated state-transition model was used to compare the health eco-
nomic outcomes over the course of one year using efﬁcacy data
from OPERA, a 3-month randomized, double-blind trial com-
paring Ditropan XL 10mg once daily to Detrol LA 4mg once
daily, together with data from the literature to project outcomes
beyond trial time. Five states were deﬁned based on the severity
of symptoms (number of incontinent episodes per week). 
Severity-speciﬁc costs (in 2003 US dollars) of pharmaceuticals,
doctor visits, and pad or protection usage for incontinence in the
US were used. RESULTS: Ditropan XL is expected to lead to
superior outcomes and lower overall costs compared to Detrol
LA. After one year, 4.6 more patients per 100 treated attain com-
plete continence and an additional 2.4 more will have fewer than
7 incontinent episodes per week. Patients on Ditropan XL have
almost 11 additional incontinence free days over the course of
the year. Costs are expected to be an average of $43 lower per
patient per year. Ditropan XL maintains its advantage over wide
ranges of inputs, and outcomes are similar if analyses are limited
to only 3 months, the duration of the OPERA trial. CONCLU-
SIONS: These analyses suggest that Ditropan XL provides better
health outcomes and lower costs compared to Detrol LA over a
1-year period.
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OBJECTIVES: The age related prevalence of Overactive Bladder
in developed economies is estimated at 17% and is comparable
with common diseases including depression, osteoporosis, and
COPD. The burden of OAB is likely to grow in the future. The
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objective of this research is to estimate current and future burden
of this condition using the UK as an example. METHODS: Age
and sex related prevalence rates have been applied to current and
forecast population data to estimate future prevalence. A pub-
lished assessment of patient costs is used to derive an estimate
of economic burden. RESULTS: Our analysis indicates that 4.7
million people are estimated to have OAB in the UK. Although
few males are treated for this disease, male prevalence is esti-
mated to account for up to 45% of the total (treated and
untreated) OAB population. UK government population fore-
casts for 2020 imply a 27% growth in OAB prevalence with male
prevalence increasing faster than that of females. Using published
data for average annual patient costs for OAB patients, the
current cost burden of OAB in the UK is estimated to exceed
£800m per annum. CONCLUSIONS: OAB is a highly prevalent
condition imposing a substantial economic burden, which will
increase with demographic shifts towards an aging population.
If the prevalence of OAB risk factors including diabetes,
smoking, and UTIs increases over time, then it is reasonable to
expect that age related OAB prevalence will increase with time.
Our forecast prevalence may therefore under-estimate future
burden because our analysis assumes that age related prevalence
is constant over time. Assuming constant costs per patient, the
economic burden will increase in line with our prevalence fore-
casts. Given that many sufferers, especially males, do not cur-
rently seek treatment, the future cost burden may also have been
underestimated.
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OBJECTIVES: In Australia, sirolimus is indicated where with-
drawal of cyclosporin (CsA) is appropriate and intended within
four months of renal transplantation. In one clinical trial,
patients randomized three months after transplantation experi-
enced signiﬁcantly lower nephrotoxicity and serum creatinine
(SC) with sirolimus and CsA withdrawal compared to a com-
bined low-dose sirolimus and CsA regimen. The long-term cost-
effectiveness of sirolimus was estimated in a cost-utility analysis
based on this trial. METHODS: A Markov model was used to
estimate sirolimus’ impact on health outcomes and direct costs
to the Australian health system for a patient’s lifetime. Graft sur-
vival rates were derived from the clinical trial data (years 1–3),
extrapolated from 6-month SC using Australia and New Zealand
Dialysis and Transplant Registry (ANZDATA) estimates (years
4–6) and assumed an exponential decay function (years 7+).
Probabilities of regraft, acute rejection and death were derived
from the clinical trial and ANZDATA data. Quality-adjusted life
years (QALYs) were the product of years with a functioning or
failed graft and time trade-off derived utilities for those health
states. Resource consequences included immunosuppressants
and inpatient and outpatient services, and were veriﬁed by a
panel of clinical experts. Estimated costs were mean national
costs to the Australian health system. RESULTS: With CsA with-
drawal, the estimated lifetime cost of immunosuppressants is
$61,804 greater, the cost of events $35,333 lower, and 0.447
additional QALYs are accrued (per-patient means). The base case
cost per additional QALY gained over combination therapy is
$59,259 and most sensitive to the cost and disutility associated
with dialysis. CONCLUSIONS: Sirolimus is associated with
greater SC reduction than CsA and is thereby expected to lead
to higher rates of graft and patient survival. It is estimated that
with CsA withdrawal, sirolimus will reduce lifetime health care
costs, increase quality-adjusted survival, and is potentially cost-
effective for recently transplanted patients.
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OBJECTIVES: Previous analyses have shown that the cost of
managing chronic kidney disease (CKD) increases with worsen-
ing disease. In this study, we were interested in the relationship
between cost of care, CKD and comorbidities (proteinuria, 
coronary artery disease, congestive heart failure (CHF), dia-
betes mellitus, hypertension, anemia, and hyperlipidemia).
METHODS: Cases were >17 years of age, and had a GFR (esti-
mated by MDRD) greater than 15ml/min/1.73m2 and less than
90ml/min/1.73m2 (the index GFR), followed by a second GFR
below 90ml/min/1.73m2 at the ﬁrst creatinine measurement that
occurred at least 90 days later; controls were matched on age
and gender. Four disease categories were established: Controls;
60–89 (GFR 2); 30–59 (GFR 3); and 15–29 (GFR 4). Subjects
were followed for 1 year and costs were annualized and weighted
by months of observation. Linear regression was used to predict
costs as a function of disease category, controlling for comor-
bidities. RESULTS: We found that patients with early and mild
chronic kidney disease (GFR 30–89) consume approximately
$2000 more per year in medical care than their age- and sex-
matched control patients without recognized kidney disease after
adjusting for comorbid conditions, while those with severe
disease (GFR 15–29) consume more than twice that amount. Of
the comorbid conditions that we evaluated, anemia, congestive
heart failure, and proteinuria were among the strongest inde-
pendent predictors of total medical costs. These conditions also
modiﬁed the total cost for each stage of chronic kidney disease.
CONCLUSION: Patients with CKD have a greater total cost of
care than age and gender matched controls, even after control-
ling for CKD-related comorbidities. Combined with increasing
incidence of kidney disease, these data strongly argue the need
for better understanding of cost-effective treatment programs in
CKD.
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OBJECTIVE: The best therapeutic approach to treating lupus
nephritis (LN) remains contentious; therefore different thera-
peutic approaches have been embraced over the years. The
purpose of this pharmacoeconomic decision analysis is to
compare the use of intermittent intravenous cyclophosphamide
plus prednisone versus oral azathioprine plus prednisone for the
treatment of LN and to determine which regimen is more bene-
ﬁcial in terms of cost. METHODS: The third party payer per-
spective was used to estimate the costs of treating LN, after
deciding to prescribe either regimen. Costs were obtained from
various sources including primary literature and clinical trials.
Analyses were based on actual costs for treatment of LN and
